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ABSTRACT
Background
Tuberculosis (TB) is still a leading cause of death worldwide. Almost a third of the world’s
population is infected with TB bacilli, and each year approximately 8 million people develop
active TB and 2 million die as a result. Today’s TB treatment, which dates back to the 1970s, is
long and burdensome, requiring at least 6 mo of multidrug chemotherapy. The situation is
further compounded by the emergence of multidrug-resistant TB (MDR-TB) and by the
infection’s lethal synergy with HIV/AIDS. Global health and philanthropic organizations are now
pleading for new drug interventions that can address these unmet needs in TB treatment.
Methods and Findings
Here we report OPC-67683, a nitro-dihydro-imidazooxazole derivative that was screened to
help combat the unmet needs in TB treatment. The compound is a mycolic acid biosynthesis
inhibitor found to be free of mutagenicity and to possess highly potent activity against TB,
including MDR-TB, as shown by its exceptionally low minimum inhibitory concentration (MIC)
range of 0.006–0.024 lg/ml in vitro and highly effective therapeutic activity at low doses in
vivo. Additionally, the results of the post-antibiotic effect of OPC-67683 on intracellular
Mycobacterium tuberculosis showed the agent to be highly and dose-dependently active also
against intracellular M. tuberculosis H37Rv after a 4-h pulsed exposure, and this activity at a
concentration of 0.1 lg/ml was similar to that of the first-line drug rifampicin (RFP) at a
concentration of 3 lg/ml. The combination of OPC-67683 with RFP and pyrazinamide (PZA)
exhibited a remarkably quicker eradication (by at least 2 mo) of viable TB bacilli in the lung in
comparison with the standard regimen consisting of RFP, isoniazid (INH), ethambutol (EB), and
PZA. Furthermore, OPC-67683 was not affected by nor did it affect the activity of liver
microsome enzymes, suggesting the possibility for OPC-67683 to be used in combination with
drugs, including anti-retrovirals, that induce or are metabolized by cytochrome P450 enzymes.
Conclusions
We concluded that based on these properties OPC-67683 has the potential to be used as a
TB drug to help combat the unmet needs in TB treatment.
The Editors’ Summary of this article follows the references.
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Tuberculosis (TB) is still a leading cause of death worldwide
[1]. Almost a third of the world’s population is infected with
TB bacilli, and each year approximately 8 million people
develop active TB and 2 million die as a result [2]. Today’s TB
treatment, which dates back to the 1970s, is long and
burdensome, requiring at least 6 mo of multidrug chemo-
therapy, typically consisting of rifampicin (RFP), isoniazid
(INH), ethambutol (EB), and pyrazinamide (PZA) given under
clinically observed conditions. The situation is further
complicated by the emergence of multidrug-resistant TB
(MDR-TB) and by the infection’s lethal synergy with HIV/
AIDS [3–6]. Patients with MDR-TB must be treated with a
combination containing second-line drugs that are less
effective, more expensive, and more toxic. TB’s lethal synergy
with HIV/AIDS puts HIV-positive individuals with latent
tubercle bacilli infection (LTBI) at a 303to 503greater risk of
developing active TB, giving rise to TB as the number one
killer among patients with AIDS [6].
The pharmaceutical industry, however, has generally shown
little interest in developing new, more effective drugs to
address these needs, and, as a result, no new anti-TB agent
with a novel mechanism of action has been launched since the
introduction of RFP in 1966. Consequently, global health and
philanthropic organizations are now pleading for new
chemotherapy interventions that can shorten the total
duration of therapy, provide improved efﬁcacy against
MDR-TB, safely treat patients co-infected with HIV/AIDS,
and target LTBI [6,7].
We initiated a program to screen for potent anti-TB agents
that have a new structure and mechanism able to inhibit the
biosynthesis of mycolic acid, and found nitro-dihydro-
imidazooxazole derivatives to exhibit such activity. Nitro-
heterocyclic compounds, including various 5- and 2-nitro-
imidazoles and 5-nitrofurans, are known to be effective
against a variety of protozoan and bacterial infections in
humans and animals [8]. These compounds, however, are also
known to commonly possess mutagenicity. CGI-17341 (Figure
1), a nitroimidazooxazole derivative, has been reported to
have anti-tubercular activity [9,10], but the compound was
not developed because of its mutagenic properties. We
focused our search on new nitro-dihydro-imidazooxazoles
with anti-tubercular activity that had no mutagenicity by
performing the bacterial reverse mutation (BRM) test [11].
About 95% of the compounds we screened earlier that had
mono- or di-alkyl substituents at 2-position were mutagenic.
However, after introducing heteroatoms to the substituent,
we were able to successfully decrease the mutagenicity rate to
16%. Among the non-mutagenic derivatives, we found OPC-
67683 to have potent anti-TB activity. We then further
evaluated OPC-67683 to determine whether the compound
could help address the unmet needs of TB treatment.
Methods
Culture Medium
Cultures of Mycobacterium tuberculosis and M. bovis BCG were
grown in Middlebrook 7H9 broth (BBL, http://www.bd.com)
and Middlebrook 7H11 agar medium (BBL), respectively.
Both types of media were prepared according to the
manufacturer’s directions.
Drug Preparation for In Vitro Studies
OPC-67683, PA-824, and CGI-17341 were synthesized at
Otsuka Pharmaceutical (http://www.otsuka.global.com); RFP,
INH, EB, streptomycin (SM), and PZA were purchased from
Sigma (http://www.sigmaaldrich.com). OPC-67683, RFP, INH,
PZA, and PA-824 were each dissolved in dimethylsulfoxide
(DMSO), and the solutions were diluted serially with DMSO in
2-fold dilutions to desired concentrations. EB and SM were
dissolved in distilled water, and the solutions were serially
diluted with distilled water in 2-fold dilutions to desired
concentrations.
Drug Preparation for In Vivo Studies
OPC-67683, PA-824, RFP, INH, EB, and PZA were each
pestled in a mortar and dissolved or suspended in 5% gum
arabic solution using an ultrasonic generator. Two-fold
dilutions were then conducted using 5% gum arabic solution
to adjust to the desired concentrations.
Strains
M. tuberculosis ATCC 25618 (H37Rv), M. tuberculosis ATCC
35838 (H37Rv-R-R), M. tuberculosis ATCC 35822 (H37Rv-H-R),
M. tuberculosis ATCC 35837 (H37Rv-E-R), M. tuberculosis ATCC
35820 (H37Rv-S-R), M. tuberculosis ATCC 35801 (Erdman), and
M. tuberculosis ATCC 35812 (Kurono) were purchased from
American Type Culture Collection (http://www.atcc.org). M.
bovis IID 982 (BCG Tokyo) was purchased from the Institute
of Medical Science, University of Tokyo. A total of 67 M.
tuberculosis strains used in this study were isolated in Japan,
Myanmar, Thailand, Cambodia, Indonesia, Vietnam, and
China.
BRM Test
The BRM test was performed in accordance with OECD
Guideline 471 using Salmonella tyiphimurium TA98, TA100,
TA1535, and TA1537, and Escherichia coli WP2 uvrA [11]. Each
bacterial strain was pre-cultured at 37 8C for 18 h using a
nutrient broth (Nissui Pharmaceutical; http://www.
nissui-pharm.co.jp/index_e.html). After adjustment to 2.4
at OD660 nm, each bacterial suspension was added to a test
tube containing the designated compound in the absence or
presence of rat liver microsome (S9) mix. After a 20-min
incubation at 37 8C, top agar was added to each test tube and
the contents were poured into minimum essential medium
(Oriental Yeast; http://www.oyc.co.jp/e/index.htm). The num-
ber of revertants was counted 48 h after incubation at 37 8C.
Susceptibility Testing
Susceptibility testing was performed using a procedure
previously reported [12,13]. Bacteria stocks preserved in a
deep freezer were each dissolved and adjusted to approx-
imately 10
6 colony-forming units (CFU)/ml. Drug-containing
plates were inoculated with the designated bacterial suspen-
sion to approximately 10
6 CFU/ml using a multipoint
inoculator (Sakuma Seisakusho; http://homepage1.nifty.com/
sakuma2000). Each plate was incubated at 37 8C for 14 d and
analyzed to determine the minimum inhibitory concentra-
tion (MIC). The MIC was expressed as the lowest concen-
tration that inhibited visible growth of organism on the agar
medium after incubation.
For the evaluation of susceptibility against clinically
isolated strains, resistance was determined based on the
following criteria recommended by the National Committee
PLoS Medicine | www.plosmedicine.org November 2006 | Volume 3 | Issue 11 | e466 2132
OPC-67683, a Promising TB Drug Candidatefor Clinical Laboratory Standards [14]: 1.0 lg/ml for RFP, 1.0
lg/ml for INH, 7.5 lg/ml for EB, and 10 lg/ml for SM. We
calculated the concentrations at which 90% of the susceptible
strains were inhibited (MIC90) and the 95% conﬁdence
intervals using the probit method.
Inhibitory Activity against Mycolic Acid Biosynthesis
M. bovis BCG cell culture was apportioned to each assay
tube at a volume of 0.98 ml, and then 0.01 ml of the test
sample solution or DMSO (vehicle control) was added. Then,
0.01 ml of 2-
14C acetic acid sodium salt was added to each
tube at 1 mCi/tube (37 Bq/tube), followed by incubation at 37
8C for 60 min. The
14C-labeled cells were harvested by
centrifugation at 2,0003g for 10 min and hydrolyzed by 2 ml
of 10% potassium hydroxide/methanol (20% potassium
hydroxide:methanol ¼ 1:1, vol/vol) at 37 8C for 1 h. After
incubation, 1 ml of 6 M hydrochloric acid was added and
mixed gently. Then, 5 ml of n-hexane was added, followed by
extraction by shaking for 20 min. Separating upper-phase
centrifugation (1,0003g for 5 min) was then performed, and
4 ml of the upper hexane phase was removed and transferred
to another tube and dried at 100 8C. For methyl esterization,
1 ml of benzene-methanol-concentrated sulfuric acid
(10:20:1, vol/vol/vol) was added and incubated at 100 8C for
1 h for drying. Then, 0.2 ml of n-hexane was added and mixed
to extract
14C-labeled fatty acid and mycolic acid. The
extracted fatty acid and the mycolic acid subclasses were
separated onto a thin-layer plate of Silicagel 60 F254 (thin-
layer chromatography plate, Merck Japan; http://www.merck.
co.jp/eng/index.html). 0.01 ml of extracted hexane phase was
applied to the plate and allowed to develop to a diameter of 4
cm in the ﬁrst solvent (heptan–diethylether–acetic acid
[94:5:1, vol/vol/vol]) and 8 cm in the second solvent (petroleum
ether–acetic acid [98:2, vol/vol]). Three thin-layer chromatog-
raphy plates were ﬁxed with an imaging plate (BAS-SR,
Fujiﬁlm; http://www.fujiﬁlm.com) and analyzed by the follow-
ing procedures:
14C-labeled fatty acid and mycolic acid were
detected using a BAS-2500 imaging system (Fujiﬁlm). The
radioactivity of each mycolic acid subclass was calculated as
photo-stimulated luminescence using Image Gauge software
(Version 2.54).
Statistical analysis was conducted, using SAS software
(R.8.1, SAS Institute; http://www.sas.com), on the values of
percent of control that were calculated automatically using
Image Gauge software (Version 2.54) based on the result of
each photo-stimulated luminescence. The signiﬁcance level of
the test was set at 5%. IC50 values (concentration required to
inhibit by 50%) and 95% conﬁdence intervals were calculated
by linear regression analysis with logarithmic transformed
concentrations.
Analysis of Metabolites Produced after Mixing OPC-67683
and M. bovis BCG Tokyo
15 llo f
14C OPC-67683 (0.5 mg/ml:1 lCi/ll) was added to
585 ll of 7H9/TN-ADC broth or bacterial culture and
incubated for 48 h. After incubation, a 2-fold volume of
acetonitrile was added and mixed well. The lysate was
centrifuged for 5 min at 15,000 rpm, and the supernatant
was analyzed using high-performance liquid chromatography
(HPLC) with ﬂow scintillation analyzer to determine the
metabolite pattern. In a parallel experiment, 0.1 ml of the
supernatant was added to the vial containing 5 ml of
Scintillation Cocktail (Ultima Gold, Perkin Elmer; http://
www.perkinelmer.com). The pellet was suspended in 600 llo f
2 M sodium hydroxide and incubated for 1 h at 60 8C, and 0.1
ml of the suspension was added to the vial containing the
Scintillation Cocktail. These samples were measured using a
Scintillation Counter (LS5000CE, Beckman; http:/www.beck-
mancoulter.com) to conﬁrm the existence of covalently
binding radioactive molecules.
Determination of the Structure of Metabolite Produced
after Mixing OPC-67683 and M. bovis BCG Tokyo
75 ll of OPC-67683 (0.5 mg/ml) was added to 2,925 llo f
7H9/TN-ADC broth or M. bovis BCG Tokyo bacterial culture
and incubated for 72 h. After incubation, a 2-fold volume of
acetonitrile was added and mixed well. The lysate was
centrifuged for 5 min at 15,000 rpm, and the supernatant
was then analyzed using LC-MS/MS to determine the
structure of the detected metabolite produced by mixing
OPC-67683 with M. bovis BCG Tokyo. The identiﬁed
metabolite was synthesized at Otsuka Pharmaceutical, and
the fragment pattern of the metabolite was then compared
with that of another compound newly synthesized based on
the predicted structure.
Activity against Intracellular Mycobacteria
Human THP-1 monocytic cells were differentiated into
macrophages by treatment with 100 ng/ml phorbol 12-
myristae 13-acetate (PMA) in RPMI-1640 medium and were
distributed at a portion of 1 3 10
6/ml after a 2-d incubation.
The differentiated macrophages were then inoculated with
6.88 log10 CFU of M. tuberculosis H37Rv for 4 h, washed twice
with the medium to roughly remove the non-infecting
bacteria, and then treated with 20 lg/ml SM for 20 h to kill
the remaining viable extracellular bacteria. The starting CFU
count in the cells was 6.42 log10 CFU. The cells were
subsequently treated with the designated test compound for
4 h and were then washed twice with fresh medium to remove
the added test compound. After an additional 68-h culture,
the cells were lysed using 0.1% SDS, and the viable bacteria
were counted in 7H11 agar plates to determine the potency
against intracellular mycobacteria.
Figure 1. Structure of CGI-17341, PA-824, and OPC-67683
OPC-67683: (R)-2-methyl-6-nitro-2-f4-[4-(4-trifluoromethoxyphenoxy)pi-
peridin-1-yl]phenoxymethylg-2,3-dihydroimidazo[2,1-b]oxazole.
doi:10.1371/journal.pmed.0030466.g001
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Mice were anesthetized by an intramuscular administration
with a 0.05-ml solution containing ketamine and xylazine
(Ketalar 50 [Sankyo; http://www.sankyo.co.jp/english]/
Serakutaru 2% [Bayer; http://www.bayer.com])/sterile physio-
logical saline solution ¼ 8:3:9), infected by an intratracheal
inoculation with a 0.05-ml cell suspension (1,010 CFU) of M.
tuberculosis Kurono using feeding needle and micro-syringe,
and housed for 28 d prior to the initiation of administration.
The designated compound dissolved or suspended in 5% gum
arabic was then administered orally. Blood samples (approx-
imately 1 ml) at each time-point were collected into a
heparinized syringe from the abdominal post cava under
ether anesthesia. The blood samples were then centrifuged
(3,000 rpm, at 5 8C) to extract the plasma. The plasma (0.1 ml)
was mixed with acetonitrile (0.2 ml) for RFP and with ethanol
(0.3 ml) for INH, EB, and PZA. For OPC-67683, the plasma
obtained was ﬁltered through a 0.22-lm ﬁlter, and then 0.1 ml
of the ﬁltered plasma was mixed with 0.5 ml of 0.5 M
carbonate buffer (pH 10) and 5 ml of diethyl ether. After
shaking for 10 min, the organic layer (4 ml) was dried using
nitrogen gas at 40 8C and dissolved with 0.2 ml of methanol/
water/formic acid (50/50/0.1). The samples were analyzed
using HPLC and high-performance liquid chromatography–
electrospray ionization–tandem mass spectrometry (LC-ESI-
MS/MS).
Therapeutic Efficacy
For evaluation of the therapeutic efﬁcacy of OPC-67683,
we designed three experiments that used various mouse
models of TB, as described below. In each experiment, the
designated compound dissolved or suspended in 5% gum
arabic was administered orally once daily. At the end of the
treatment period, the mice were euthanized (exsanguination
through the abdominal inferior vena cava) under ether
anesthesia, and the lung was aseptically excised. A lung
homogenate for each mouse was prepared by pestling the
lung evenly with a glass homogenizer after adding sterile
distilled water to the excised lungs, and the homogenate was
then diluted further with distilled water. A smear plate for
each lung homogenate was then prepared by spreading 0.1 ml
of each diluted solution on a 7H11 agar plate using a
spreader. After spreading the homogenate solution, all plates
were incubated at 37 8C and counted for formed colonies
after 14 d.
Therapeutic efﬁcacy in an experimental mouse model of
chronic TB. In order to examine the therapeutic efﬁcacy of
OPC-67683 and to determine the therapeutic dose range, an
experimental mouse model of chronic TB was established by
inoculating Institute of Cancer Research (ICR) mice with M.
tuberculosis Kurono through the caudal vein and allowing the
infection to develop for 28 d. OPC-67683, RFP, INH, EB, SM,
or PZA was then administered once daily for 28 d to examine
the change in viable bacterial count in the lung. ICR mice
were inoculated intravenously with 8.6 3 10
4 CFU of M.
tuberculosis Kurono. After a 28-d period, the mice were
assigned to groups (n ¼ 5/group) using a stratiﬁed random-
ization method based on the body weight of each infected
mouse. The test compounds were then administered orally
once daily for 28 d (OPC-67683: 40 to 0.156 mg/kg, RFP: 20 to
1.25 mg/kg, INH: 20 to 1.25 mg/kg, EB: 160 to 20 mg/kg, SM:
160 to 20 mg/kg, PZA: 320 to 40 mg/kg, and PA-824: 40 to 1.25
mg/kg [2-fold dilutions]). CFU counts were performed as
described above. All lungs were homogenized with 5 ml of
sterile distilled water.
Statistical analysis was conducted using SAS software
(R.8.1) on the number of viable bacteria in the lung of mice
surviving until necropsy on the 57th day after inoculation,
and on the number at the start of the treatment, which was on
the 29th day after inoculation. The signiﬁcance level of the
test was set at 5%. A test for dose dependency was performed
using linear regression analysis based on log-transformed
values of the viable bacterial counts in the lung. When dose
dependency was conﬁrmed, the Williams’ test (lower-tailed)
was subsequently performed, and when dose dependency was
not conﬁrmed, the Dunnett’s test (two-tailed) was subse-
quently performed against each of the control groups.
Therapeutic efﬁcacy in an experimental TB model using
immunocompromised mice. To examine whether immunity
relates to the mechanism of action in vivo, we performed
experiments using BALB/c nude mice, which lack both
conventional CD4
þ and CD8
þ T cells. The anti-tubercular
activity of OPC-67683 in nude mice was compared with that
in immunocompetent mice. BALB/c nude mice and BALB/c
mice were inoculated intravenously with 2.04310
4 CFU of M.
tuberculosis Kurono. 1 d after inoculation, the mice were
assigned to groups (n ¼ 5/group) using a stratiﬁed random-
ization method based on the body weight of each infected
mouse. OPC-67683 was then administered orally once daily
for 10 d (OPC-67683: 10 to 0.313 mg/kg [2-fold dilutions]).
CFU counts were performed as described above. All lungs
were homogenized with 5 ml of sterile distilled water.
Therapeutic efﬁcacy in combination with conventionally
used drugs. A new regimen that included OPC-67683 was
evaluated and compared with a global standard regimen to
determine the best regimen for reducing the treatment
duration in an experimental mouse model of chronic TB. ICR
mice were inoculated intratracheally under anesthesia with
855 CFU of M. tuberculosis Kurono, and left for 28 d to allow
the animals to develop chronic TB. Grouping (n ¼ 6/group)
was conducted by a stratiﬁed randomization method based
on the body weight of each infected mouse. The test regimens
were then administered orally for 2 mo in the combination of
OPC-67683, RFP, and PZA, or RFP, INH, EB, and PZA as an
intensive treatment, and for an additional 2 mo in the
combination of OPC-67683 and RFP or 4 mo in the
combination of RFP and INH as a maintenance treatment.
The doses used in this experiment provided plasma levels in
mice similar to those seen at the standard doses used in
humans: for RFP, we used 5 mg/kg; for INH, 10 mg/kg; for EB,
100 mg/kg; and for PZA, 100 mg/kg. We set the dose for OPC-
67683 at 2.5 mg/kg.
Necropsy was performed on days 29, 57, 85, 113, 141, 169,
and 177 relative to the inoculation for the standard regimen
and vehicle control groups and on days 29, 57, 85, 113, and
141 for the new-regimen groups. A lung homogenate for each
mouse from a drug-treated group was prepared by pestling
the lung evenly with a glass homogenizer after adding to the
excised lungs 5 ml of sterilized distilled water on day 29 and 2
ml of sterilized distilled water on the day of necropsy. Lung
homogenates for all vehicle control groups were prepared by
pestling the lung evenly with a glass homogenizer after adding
5 ml of sterilized distilled water to the excised lungs. Smear
plates of lung homogenate samples from the groups after 2–6
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homogenate on 7H11 agar plates.
Statistical analysis was conducted using SAS software
(R.8.1) on the viable bacteria number in the lungs of mice
surviving until necropsy after the inoculation. The signiﬁ-
cance level of the test was set at 5%. The viable bacterial
count in the lungs of mice anatomized at days 57, 85, 113, and
141 were log-transformed for comparing the new regimen
with the standard regimen using the two-tailed Dunnett’s test.
The mean values and 95% conﬁdence intervals were
calculated for evaluating the new regimen.
In Vitro Metabolism of OPC-67683 in Human and Animal
Liver Microsomes
The study was undertaken to investigate the metabolites
produced by the metabolic reactions of OPC-67683 using
human, rat, mouse, dog, rabbit, and monkey liver micro-
somes. Pooled human liver microsomes (20 mg/ml) from ten
donors were prepared at the Biomedical Research Institute,
Human and Animal Bridge Discussion Group (Chiba, Japan)
[15]. Human liver samples were legally procured from the
National Disease Research Interchange (http://www.
ndriresource.org/) through the international partnership with
the Human and Animal Bridge Discussion Group. The study
was conducted in accordance with the Declaration of
Helsinki.
The incubation mixtures contained 100 mM phosphate
buffer (pH 7.4), 100 lM OPC-67683, 2.5 mM b-NADPH, 2.5
mM b-NADH, and 1 mg/ml microsomal protein in a ﬁnal
incubation volume of 0.5 ml. OPC-67683 was dissolved in
DMSO, and the concentration of the organic solvent was 1%
(v/v) in the reaction system. The reactions were performed in
duplicate in a shaking water bath at 37 8C for 2 h. The
incubation mixtures were extracted with acetonitrile and
ethyl acetate, and the samples were analyzed by HPLC and
LC-ESI-MS/MS.
Effect of OPC-67683 on Cytochrome P450–Mediated
Reactions in Human Liver Microsomes
7-ethoxyresoruﬁn O-deethylase activity by CYP1A1/2, cou-
marin 7-hydroxylase activity by CYP2A6, 7-benzyloxyresor-
uﬁn O-debenzylase activity by CYP2B6, tolbutamide
methylhydroxylase activity by CYP2C8/9, S-mephenytoin 49 -
hydroxylase activity by CYP2C19, bufuralol 19 -hydroxylase
activity by CYP2D6, chlorzoxazone 6-hydroxylase activity by
CYP2E1, and testosterone 6b-hydroxylase and nifedipine
oxidized activities by CYP3A4 were determined as previously
reported [16].
Standard incubation mixtures of 0.5 ml contained micro-
somal protein (0.1–0.5 mg), 0.1 M potassium phosphate buffer
(pH 7.4), 0.1 mM EDTA, NADPH-generating system (2.5 mM
b-NADP, 25 mM glucose-6-phosphate, 2 units of glucose-6-
phosphate dehydrogenase, and 10 mM magnesium chloride),
and substrates with or without OPC-67683. OPC-67683 was
dissolved in DMSO and added to incubations at a volume of 5
ll. Substrates were dissolved in the following solvents: 7-
ethoxyresoruﬁn and 7-benzyloxyresoruﬁn in DMSO; coumar-
in, bufuralol, and nifedipine in ethanol; tolbutamide, S-
mephenytoin and testosterone in methanol; and chlorzox-
azone in 1% (w/v) aqueous solution. The substrate solutions
were added to incubations at a volume of 5 ll. The enzyme
incubations were carried out in duplicate, and formations of
metabolites were determined by HPLC.
Assay methods were validated in this study. The calibration
curves were established for resoruﬁn (0.2–200 nM, r¼0.9996),
7-hydroxycoumarin (0.05–5 lM, r ¼ 0.9998), 4-hydroxytolbu-
tamide (0.05–10 lM, r ¼ 0.9998), 4-hydroxymephenytoin
(0.025–5 lM, r ¼ 0.9996), 19 -hydroxybufuralol (0.025–5 lM,
r ¼ 0.9995), 6-hydroxychlorzoxazone (0.25–100 lM, r ¼
0.9994), 6b-hydroxytestosterone (0.03–30 lM, r ¼ 0.9994),
and oxidized nifedipine (0.1–25 lM, r ¼ 0.9998).
7-ethoxyresoruﬁn (0.5 lM), coumarin (2 lM), 7-benzylox-
yresoruﬁn (1.5 lM), tolbutamide (400 lM), S-mephenytoin
(100 lM), bufuralol (20 lM), chlorzoxazone (100 lM),
testosterone (100 lM), and nifedipine (50 lM) were selected
as the concentrations of the substrates for the determination
of residual activity in the presence of OPC-67683 (1–100 lM).
The concentrations of the substrates were approximately the
Km values for the enzymes as previously reported [17].
Selective Cytochrome P450 inhibitors were used in this study
to conﬁrm the validity of the assays. 7,8-benzoﬂavone [18],
furafylline [19], orphenadrine [20], quercetin [21], sulfaphe-
nazole [22], tranylcypromine [23], quinidine [24], diethyldi-
thiocarbamate [25], and ketoconazole [26], which are
inhibitors of CYP1A1, 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1,
and 3A4, respectively, inhibited the respective enzyme
Table 1. Bacterial Reverse Mutation Test for OPC-67683
Bacterial Strain S9 mix Compound Revertants/Plate
5,000 2,500 1,250 625 312.5 0 lg/plate
S. typhimurium TA98   OPC-67683 AF-2(0.1 lg/plate) 31 37 34 29 29 29 473
þ OPC-67683 2AA(0.5 lg/plate) 35 31 30 31 31 36 92
S. typhimurium TA100   OPC-67683 AF-2(0.01 lg/plate) 94 90 87 77 85 98 547
þ OPC-67683 2AA(1 lg/plate) 119 112 107 108 116 108 1103
S. typhimurium TA1535   OPC-67683 NaN3(0.5 lg/plate) 6 7 6 9 6 6 174
þ OPC-67683 2AA(2 lg/plate) 9 8 5 6 5 6 188
S. typhimurium TA1537   OPC-67683 ACR(80 lg/plate) 63 61 54 62 60 64 953
þ OPC-67683 2AA(2 lg/plate) 74 63 66 72 73 81 238
E. coli WP2 uvr A   OPC-67683 AF-2(0.01 lg/plate) 24 24 20 25 23 30 225
þ OPC-67683 2AA(10 lg/plate) 29 23 25 20 23 33 1122
AF-2, 2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide; 2AA, 2-aminoanthracene; NaN3, sodium azide; ACR, 9-aminoacridine.
doi:10.1371/journal.pmed.0030466.t001
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OPC-67683, a Promising TB Drug Candidateactivities. Diethyldithiocarbamate is also known to be a
speciﬁc inhibitor of CYP2A6 [18], and the present study
conﬁrmed the potent inhibitory capability of this compound
on CYP2A6-mediated metabolism.
Other Information
The care and handling of the animals was in accordance
with ‘‘Guidelines for Animal Care and Use in Otsuka
Pharmaceutical Co., Ltd.’’ The aspects of experiments related
to biosafety were performed according to standards set forth
in ‘‘Biosafety manuals in Microbiological Research Institute
and 3rd Institute of New Drug Discovery, Otsuka Pharma-
ceutical Co., Ltd.’’
Results
BRM Test
The mutagenic potential of OPC-67683 was evaluated in
the absence and presence of S9 mix using the BRM test in
accordance with OECD Guideline 471. As shown in Table 1,
OPC-67683 did not show mutagenicity.
Susceptibility Testing
The MICs against standard strains are shown in Table 2. At
concentrations ranging from 0.006 to 0.012 lg/ml, OPC-67683
inhibited the growth of both drug-susceptible and drug-
resistant M. tuberculosis. The MICs of OPC-67683 were,
respectively, four to 64, two to 32, 128 to 256, 64 to 512,
eight to 16, and four to 16 times lower than those of RFP,
INH, EB, SM, CGI-17341, and PA-824. These results indicate
that OPC-67683 possesses the most potent anti-mycobacterial
activity against both drug-susceptible and drug-resistant
strains.
The anti-tubercular activity was also evaluated on 67
clinically isolated strains. The MIC90 values (range) of OPC-
67683, RFP, INH, EB, and SM were, respectively, 0.012 lg/ml
(0.006–0.024 lg/ml), 0.288 lg/ml (0.05–0.78 lg/ml), 0.099 lg/ml
(0.05–0.78 lg/ml), 3.636 lg/ml (0.78–6.25 lg/ml), and 2.938 lg/
ml (0.39–6.25 lg/ml). Based on these results, the MIC90 values
of OPC-67683 were about 24, eight, 303, and 244 times lower
than those of RFP, INH, EB, and SM, respectively. The results
of our evaluation indicated that OPC-67683 inhibited the
growth of the clinically isolated drug-susceptible M. tuber-
culosis at the same range as on standard strains, and also
showed activity against the clinically isolated strains resistant
to the currently used anti-TB drugs RFP, INH, EB, or SM.
These results indicate that OPC-67683 exhibits anti-myco-
bacterial activity on both drug-susceptible and drug-resistant
strains and that it has no cross-resistance with any of the
currently used anti-TB drugs. These data are shown in Table 3.
In addition, the efﬁcacy of OPC-67683 in combination with
currently used anti-TB drugs RFP, INH, EB, and SM was
examined in vitro using the checkerboard method. These
results are shown in Table 4. The results showed OPC-676783
to have no antagonistic activity in combination with any of
the drugs tested.
Inhibitory Activity against Mycolic Acid Biosynthesis
14C-labeled fatty acid and mycolic acid were detected using
the BAS-2500 imaging system (unpublished data). The
percent with respect to the control of each mycolic acid
subclass was calculated automatically, and IC50 was calculated
using SAS software. The results indicated that both OPC-
67683 and INH inhibited mycolic acid synthesis, but the
manner of action differed between the two compounds: OPC-
67683 inhibited the synthesis of methoxy- and keto-mycolic
acid, with IC50 values of 0.021 to 0.036 lg/ml, but not the
synthesis of a-mycolic acid at concentrations up to 0.25 lg/ml,
while INH inhibited all mycolic acid subclasses, with IC50
values of 0.630 to 1.851 lg/ml. The IC50 and 95% conﬁdence
interval values are shown in Table 5.
Table 2. In Vitro Anti-Mycobacterial Activity of OPC-67683 Compared with RFP, INH, EB, SM, CGI-17341, and PA-824
Type Strain MIC (lg/ml)
OPC-67683 RFP INH EB SM CGI-17341 PA-824
M. tuberculosis ATCC 25618 (H37Rv) 0.012 0.78 0.1 1.56 1.56 0.2 0.2
M. tuberculosis ATCC 35838 (H37Rv-R-R) 0.006 .100 0.1 1.56 0.78 0.05 0.1
M. tuberculosis ATCC 35822 (H37Rv-H-R) 0.012 0.39 .100 3.13 0.78 0.2 0.05
M. tuberculosis ATCC 35837 (H37Rv-E-R) 0.012 0.2 0.2 50 0.78 0.2 0.2
M. tuberculosis ATCC 35820 (H37Rv-S-R) 0.012 0.78 0.1 3.13 .100 0.2 0.2
M. tuberculosis ATCC 35812 (Kurono) 0.012 0.39 0.1 3.13 0.78 0.2 0.2
Susceptibility of OPC-67683 against standard M. tuberculosis.
doi:10.1371/journal.pmed.0030466.t002
Table 3. MIC90 of OPC-67683 against Drug-Susceptible and
Drug-Resistant M. tuberculosis
Organism Group
(Number of Strains)
MIC (lg/ml)
MIC90 95% Confidence
Intervals
RFP-susceptible M. tuberculosis (31) 0.01248 0.01097–0.01535
RFP-resistant M. tuberculosis (36) 0.01221 0.01050–0.01583
INH-susceptible M. tuberculosis (31) 0.01194 0.01054–0.01452
INH-resistant M. tuberculosis (36) 0.01279 0.01094–0.01679
EB-susceptible M. tuberculosis (56) 0.01213 0.01081–0.01440
EB-resistant M. tuberculosis (11) 0.01341 0.01073–0.02450
SM-susceptible M. tuberculosis (49) 0.01203 0.01077–0.01416
SM-resistant M. tuberculosis (18) 0.0134 0.01068–0.02298
Susceptibility of OPC-67683 against 67 strains of clinically isolated M. tuberculosis:
Resistant strains were selected based on the recommendations of the National
Committee For Clinical Laboratory Standards [14] using the following criteria: 1.0 lg/ml
for RFP, 1.0 lg/ml for INH, 7.5 lg/ml for EB, and 10 lg/ml for SM. We calculated the
concentrations at which 90% (MIC90) of the susceptible strains are inhibited. MIC90 and
95% confidence intervals were calculated using the actual data obtained by the probit
method.
doi:10.1371/journal.pmed.0030466.t003
PLoS Medicine | www.plosmedicine.org November 2006 | Volume 3 | Issue 11 | e466 2136
OPC-67683, a Promising TB Drug CandidateAnalysis of Metabolites Produced after Mixing OPC-67683
and M. bovis BCG
After mixing OPC-67683 with M. bovis BCG Tokyo, we
identiﬁed only one main metabolite, and this metabolite
eluted faster than OPC-67683. No metabolites, however, were
observed after mixing OPC-67683 with an experimentally
obtained OPC-67683-resistant M. bovis BCG Tokyo strain.
These results are shown in Figure 2A. The supernatant was
analyzed using LC-MS/MS to determine the structure of the
identiﬁed metabolite. We found the mass number of the
identiﬁed metabolite to be 490 and predicted this structure
to be a desnitro-imidazooxazole. We then synthesized a
desnitro-imidazooxazole and performed a product ion scan
with the identiﬁed metabolite and the newly synthesized
compound. We observed product ions in 200, 352, 378, and
406 m/z in each experiment. Structural analysis of the main
metabolite indicated that the structure was a desnitro-
imidazooxazole possessing the same substituent as that of
OPC-67683. The MS spectrum is displayed in Figure 2B.
In addition, when we treated the drug-susceptible strain
with the radioactive OPC-67683, none of the radioactivity was
recovered after the addition of acetonitrile. About 20% of
the total radioactivity was distributed to the cell components,
and this phenomenon was not observed with an OPC-67683-
resistant strain. These data are shown in Table 6.
Activity against Intracellular Mycobacteria in Human
Macrophages
A study was conducted to conﬁrm the post-antibiotic effect
of OPC-67683 on intracellular M. tuberculosis in THP-1 cells,
and the results were compared with RFP, INH, and PA-824.
OPC-67683 was shown to be highly active against intracellular
M. tuberculosis H37Rv after 4-h pulsed exposures in a dose-
dependent manner. The data are shown in Figure 3. The
intracellular activity of OPC-67683 at a concentration of 0.1
lg/ml was similar to that of RFP of 3 lg/ml, but was superior to
INH and PA-824, which both showed poor activity during the
4-h pulsed exposure. These results indicated that even with
limited contact with the bacteria within the cells, OPC-67683
might be able to effectively kill the intracellular mycobacteria.
Plasma Levels in an Experimental Mouse Model of TB
As shown in Table 7, OPC-67683 exhibited the lowest
plasma concentration but longest half-life among the tested
reference drugs. The Cmax and AUCt values for RFP, EB, and
PZA in mouse plasma at the tested dose were similar to those
in human at clinical doses. The Cmax value for INH in mouse
plasma was also similar to that in humans, but the AUCt in the
mouse was lower than that in humans. A comparison of these
parameters between mouse and human plasma is summarized
in Figure 4C [27–29].
Therapeutic Efficacy
Therapeutic efﬁcacy in an experimental mouse model of
chronic TB. The viable bacterial count in the OPC-67683-
treated groups decreased dose-dependently, and the ther-
apeutic effects of the compound were observed and com-
pared with those of the reference drugs. The results are
shown in Figure 4A and Table S1. The dose groups that
showed a signiﬁcant decrease in pulmonary viable bacterial
count when compared with the vehicle control group were
Table 4. In Vitro Synergistic Activity of OPC-67683 and Existing
TB Drugs against Clinically Isolated M. tuberculosis
Drug
Combination
Number of Test Strains for which FIC Index Is:
Synergistic Partially
Synergistic
Additive Indifferent
OPC-67683
and RFP
1 (3.7%) 24 (88.9%) 2 (7.4%) —
OPC-67683
and INH
— 12 (44.4%) 5 (18.5%) 10 (37.0%)
OPC-67683
and EB
3 (11.1%) 21 (77.8%) 3 (11.1%) —
OPC-67683
and SM
— 7 (25.9%) 10 (37.0%) 10 (37.0%)
In vitro synergistic activity of OPC-67683 and existing TB drugs against clinically isolated
M. tuberculosis: The checkerboard procedure was performed based on the MIC values of
27 test strains of clinically isolated M. tuberculosis established by the agar dilution method.
The level of synergy was determined by calculating the fractional inhibitory concentration
(FIC) index based on the following formula: FIC of drug A¼MIC of drug A in combination
4 MIC of drug A alone; FIC of drug B ¼ MIC of drug B in combination 4 MIC of drug B
alone; and FIC index¼FIC of drug AþFIC of drug B. Results of FIC index were interpreted
as follows:  0.5: synergy, .0.5 to 0.75: partial synergy, .0.75 to 1.0: additive effect, .1.0
to 4.0: indifference, and .4.0: antagonism. We calculated the FIC index value for each
concentration of two-drug combination and the minimum value was adopted.
doi:10.1371/journal.pmed.0030466.t004
Table 5. IC50 of OPC-67683 and INH against Mycolic Acid Synthesis
Compound Subclass Mycolic Acid and Fatty Acid IC50 (lg/ml) 95% Confidence Interval (lg/ml)
OPC-67683 Fatty acid .0.25 —
a-Mycolic acid .0.25 —
Methoxy-mycolic acid 0.036 0.020–0.068
Keto-mycolic acid 0.021 0.009–0.059
INH Fatty acid .4—
a-Mycolic acid 1.851 1.109–3.090
Methoxy-mycolic acid 0.63 0.537–0.738
Keto-mycolic acid 0.69 0.422–1.129
The IC50 (concentration required to inhibit activity by 50%) of OPC-67683 against mycolic acid synthesis in M. bovis BCG was determined and compared with that of INH, a well-known
inhibitor of mycolic acid synthesis.
14C-labeled acetic acid was incorporated to mycolic acid by incubation with M. bovis BCG cell cultures in the presence of OPC-67683 or INH as a
reference.
14C-labeled fatty acid and mycolic acid subclasses were detected using thin-layer chromatography (TLC, n ¼ 3), and analyzed by BAS-2500 (Fujifilm). The radioactivity of each
fatty acid and mycolic acid subclasses was calculated using photo-stimulated luminescence, expressed as the percentage of incorporation in untreated controls, and statistical analysis was
conducted by linear regression analysis to calculate IC50 values and 95% confidence intervals (significance level: 5%).
doi:10.1371/journal.pmed.0030466.t005
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OPC-67683, a Promising TB Drug Candidate0.313, 0.625, 1.25, 2.5, 5, 10, 20, and 40 mg/kg for OPC-67683;
3.5, 5, 10, and 20 mg/kg for RFP; 2.5, 5, 10, and 20 mg/kg for
INH; 160 mg/kg for EB, 20, 40, 80, and 160 mg/kg for SM; and
80, 160, and 320 mg/kg for PZA.
The doses of OPC-67683, RFP, INH, EB, SM, and PZA that
could produce a CFU reduction of at least 95% in this
experimental mouse model were 0.625, 3.5, 5, .160, 40, and
160 mg/kg, respectively.
Therapeutic efﬁcacy in an experimental TB model using
immunocompromised mice. These results are shown in
Figure 4B.
The pulmonary CFU counts of the OPC-67683-treated
Figure 2. Analysis of Metabolites Produced after Mixing OPC-67683 and M. bovis BCG
(A) 15 llo f
14C OPC-67683 (0.5mg/ml: 0.056 lCi/ll) was added to 585 ll of 7H9/TN-ADC broth or bacterial culture and incubated for 48 h. After
incubation, a 2-fold volume of acetonitrile was added and mixed well. The lysate was centrifuged for 5 min at 15,000 rpm. The supernatant was
analyzed using HPLC with flow scintillation analyzer to determine the metabolite pattern.
(B) The identified metabolite (desnitro-imidazooxazole) was synthesized at Otsuka Pharmaceutical, and the fragment pattern of the metabolite by
electrospray ionization mass spectroscopy was then compared with that of another compound newly synthesized based on the predicted structure.
doi:10.1371/journal.pmed.0030466.g002
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OPC-67683, a Promising TB Drug CandidateBALB/c nude mice and immunocompetent mice were
reduced dose-dependently, and signiﬁcant decreases were
observed at doses of 0.313, 0.625, 1.25, and 2.5 mg/kg. The
efﬁcacy proﬁles of OPC-67683 were similarly excellent in
both types of mice.
Therapeutic efﬁcacy in combination with conventionally
used drugs. The eradication rate of a new regimen containing
OPC-67683 was compared with that of the standard regimen.
The OPC-67683-containing regimen exerted a rapid and
consistent reduction during the ﬁrst 3 mo (Figure 4D). At 3
mo after the start of treatment, only one colony was detected
in one of the six animals; at 4 mo, no colonies were detected
in any of the six animals. In contrast, at 6 mo for the standard
regimen, colonies were detected in four out of ﬁve mice.
These results suggest that a new regimen containing OPC-
67683 could dramatically reduce the treatment duration by at
least 2 mo.
In Vitro Metabolism in Human and Animal Liver
Microsomes
The current study was conducted to investigate the
metabolites produced by in vitro metabolism of OPC-67683
using human and animal liver microsomes and to investigate
the in vitro ability of OPC-67683 to affect the metabolism of
substrates for CYP1A1/2, CYP2A6, CYP2B6, CYP2C8/9,
CYP2C19, CYP2D6, CYP2E1, and CYP3A4. The results are
shown in Table 8.
The HPLC and LC-ESI-MS/MS data demonstrated that the
major metabolites were hardly detected in the incubation
mixture OPC-67683 with human, rat, mouse, dog, rabbit, and
monkey liver microsomes. OPC-67683 was stable in the in
vitro metabolism of human and animal liver microsomes.
These results suggest that OPC-67683 is not metabolized by
the CYP enzymes.
OPC-67683 had neither stimulatory nor inhibitory effects
on CYP1A1/2, CYP2A6, CYP2B6, CYP2C8/9, CYP2C19,
CYP2D6, CYP2E1, and CYP3A4 activities at concentrations
up to 100 lM, indicating that OPC-67683, at the expected
therapeutic concentrations, would not be predicted to cause
clinically signiﬁcant interactions with other CYP-metabolized
drugs.
Discussion
With the several disadvantages to the current TB drug
regimen, there are a number of expectations for a new anti-
TB drug. An ideal new drug should be safe and able to
shorten the treatment duration, be effective against MDR-TB,
treat TB patients co-infected with HIV, and effectively
address LTBI. We have performed our TB research program
with these expectations in mind.
To shorten the duration of treatment, we focused our
search on ﬁnding more powerful anti-TB agents, as history
has shown that the introduction of more potent drugs can
effectively reduce the required duration of treatment, as was
the case with RFP and PZA. For improved efﬁcacy against
MDR-TB, we screened for compounds with a new structure
and mechanism of action. Furthermore, to target LTBI, we
Table 6. Analysis of OPC-67683-Susceptible and -Resistant M. bovis BCG Using Radio-Labelled OPC-67683
Sample Total DPM Percent
Supernatant Pellet Sample DPM (Supernatant)/
Control DMP (Supernatant)
Sample DPM (Pellet)/
Control DMP (Supernatant)
Control 823295.30 24558.06 100 3
M. bovis BCG
Tokyo
678566.21 182886.84 82 22
M. bovis BCG Tokyo
OPC-resistant
862893.41 43158.12 105 5
15 llo f
14C OPC-67683 (0.5mg/ml:0.056 lCi/ll) was added to 585 ll of 7H9/TN-ADC broth or bacterial culture and incubated for 48 h. After incubation, a 2-fold volume of acetonitrile was
added and mixed well. The lysate was centrifuged for 5 min at 15,000 rpm and 0.1 ml of the supernatant was added to the vial containing 5 ml of Scintillation Cocktail (Ultima Gold,
PerkinElmer). The pellet was suspended in 600 ll of 2 M NaOH and incubated for 1 h at 60 8C, and 0.1 ml of the suspension was added to the vial containing 5 ml Scintillation Cocktail.
These samples were measured using a Scintillation Counter (LS5000CE, Beckman).
doi:10.1371/journal.pmed.0030466.t006
Figure 3. Effect of Pulsed Exposures to OPC-67683, RFP, INH, and PA-824
on the Intracellular Growth of M. tuberculosis H37Rv within THP-1 Cells
Infected cells were incubated with the test compound for 4 h, washed,
cultured until68 h at 37 8C, plated on 7H11agar, and counted for colonies
after 16 d of growth at 37 8C. Values represent mean 6 S.D (n ¼3).
doi:10.1371/journal.pmed.0030466.g003
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OPC-67683, a Promising TB Drug Candidatefocused on compounds with activity against intracellular M.
tuberculosis.
Mycobacteria are well known to be wax-rich bacteria, and a
main component of the wax is mycolic acid, which is detected
only in mycobacteria and not in gram-positive or gram-
negative bacteria or in mammalian cells. Genome research of
tubercle bacilli has veriﬁed this lipid richness, showing there
to be almost 250 distinct enzymes involved in the lipid
metabolism of tubercle bacilli [30]. In view of the important
role of mycolic acid in mycobacteria, we searched for a
compound that could inhibit mycolic acid synthesis and
demonstrate potent anti-TB activity in vitro. We found OPC-
67683 to have both inhibitory activity on mycolic acid
biosynthesis and potent in vitro activity against M. tuberculosis,
as indicated by its low MIC range across many strains,
including MDR-TB. The IC50 values of OPC-67683 for
mycolic acid subclasses were lower than those of INH, and
these results correlated well with the in vitro anti-tubercular
activity of OPC-67683 and INH. The anti-tubercular activity
of nitro-imidazooxazole derivatives correlated well with their
inhibitory activity against mycolic acid biosynthesis [11]. We
therefore concluded that the inhibitory activity of OPC-
67683 against mycolic acid synthesis was a mechanism of
action attributable to killing mycobacteria at least as potently
as INH.
As M. tuberculosis can grow not only facultatively but also as
intracellular organisms that survive and multiply in macro-
phages of the infected host, we consider it important that a
compound is also able to kill intracellular TB and that such
activity should correlate with a shortened treatment duration
and could be an important factor in the treatment of LTBI.
We therefore examined the killing activity against intra-
cellular TB in macrophage-derived THP-1 cells. Among the
tested compounds, OPC-67683 demonstrated the most
potent killing activity. The killing activity of OPC-67683 at
0.1 lg/ml was similar to that of RFP at 3 lg/ml and was
superior to that of INH and PA-824. The intracellular
potency of antibiotics is commonly evaluated in vitro using
continuous exposure rather than in animal models due to
their often-rapid elimination, depending on the plasma half-
life. OPC-67683 was able to demonstrate potent in vitro
killing ability even at short exposure times. These results
indicate that OPC-67683 would likely exert strong antibiotic
activity against intracellular TB in patients even at short
exposure times, which could be an advantage in intermittent
treatment.
PA-824 has been reported to be a prodrug metabolized to
its active form by mycobacterium [31]. Recently, Manjunatha
et al reported that Rv3547 acts as the catalytic enzyme for PA-
824, but the role of Rv3547 within mycobacterium is not yet
clear [32]. Similarly, OPC-67683 also requires metabolic
activation by M. tuberculosis in order for the anti-TB activity
to be exerted. Experimentally isolated OPC-67683-resistant
mycobacterium did not metabolize the compound. We
conﬁrmed a mutation in the Rv3547 gene among the resistant
organisms, indicating Rv3547 to be a key enzyme involved in
activating OPC-67683, as it was for PA-824 (unpublished
data). According to Manjunatha et al, the metabolites of PA-
824 have not yet been identiﬁed. With OPC-67683, however,
the main metabolite produced in the presence of M.
tuberculosis was identiﬁed as a non-active desnitro-imidazoox-
azole. This result suggests that Rv3547 possesses a reduction
potency of the nitro residue and that an intermediate
between OPC-67683 and the desnitro-imidazooxazole could
be the active form. After mixing radioactive OPC-67683 with
viable mycobacterium, nearly 20% of the radioactive sub-
stances were not recovered. In contrast, after treating OPC-
67683-resistant mycobacterium, nearly 100% of radioactivity
was recovered. The action mechanism of metronidazole
derivatives against H. pylori has been reported to be due to
the production of a radical intermediate [33]. This informa-
tion suggests the possibility that a radical intermediate that
appears as the intermediate for the metabolism of a nitro
residue covalently binds to the target molecule. If this
hypothesis is correct, it could well explain the strong post-
antibiotic effect seen with OPC-67683 against intracellular
mycobacterium, a property considered necessary to kill latent
TB.
The therapeutic efﬁcacy of OPC-67683 was evaluated in
vivo in an experimental chronic TB mouse model. In this
Table 7. Plasma Concentration of OPC-67683, RFP, INH, EB, and PZA after Oral Administration in Mice Infected with M. tuberculosis
Kurono
Compound
(Dose;
mg/kg)
Concentration (lg/ml) Cmax
(lg/ml)
AUCt
(lg   h/ml)
tmax
(h)
t1/2
(h) 0.083 h 0.25 h 0.5 h 1 h 2 h 4 h 6 h 8 h 12 h 16 h 24 h
OPC-67683
(2.5)
N.T. N.T. N.T. 0.133
60.030
0.193
60.040
0.220
60.020
0.297
60.083
0.167
60.028
0.166
60.049
N.T. 0.049
60.012
0.297 4.13 6 7.6
RFP (5) N.T. N.T. 3.33
60.87
4.49
61.04
4.52
61.90
3.82
60.70
5.10
61.63
3.18
60.68
N.T. 0.660
60.260
N.T. 5.10 48.2 6 3.4
INH (10) 2.17
60.435
3.06
60.779
2.28
60.390
1.92
60.478
0.740
60.202
0.253
60.057
N.T. N.D. N.T. N.T. N.T. 3.06 4.55 0.25 1.0
EB (100) 0.055
60.049
1.30
60.939
3.17
60.392
3.51
61.13
2.51
61.01
1.02
60.202
N.T. 0.612
60.325
N.T. N.T. N.T. 3.51 12.2 1 2.8
PZA (100) 49.6
611.2
59.1
614.1
63.2
628.9
60.2
618.7
35.5
66.45
18.4
63.09
N.T. 0.815
60.580
N.T. N.T. N.T. 63.2 197 0.5 1.1
Each value represents mean 6 SD (n ¼ 3).
Each pharmacokinetic parameter was calculated by WINNONLIN (Version 4.1).
N.D., not detected (,0.05 lg/ml for INH); N.T., not tested.
doi:10.1371/journal.pmed.0030466.t007
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OPC-67683, a Promising TB Drug Candidatemodel, OPC-67683 exhibited the most potent anti-tubercular
activity in comparison with the reference compounds. The
viable bacterial counts in the lung were markedly reduced
dose-dependently by OPC-67683 at 0.313 mg/kg and higher. A
95% reduction in bacterial load was achieved at 0.625 mg/kg.
Furthermore, the efﬁcacy of OPC-67683 in a TB model
established using immunodeﬁcient mice was similar to that
seen using standard mice.
Treatment of TB requires combination therapy not only to
shorten the treatment duration but also to prevent the
development of resistance. The effects of OPC-67683 in
combination with currently used TB drugs were therefore
evaluated both in vitro and in vivo. OPC-67683 did not exert
antagonistic effects in any of the tested combinations, and
produced partial synergistic or synergistic effects when
combined with RFP or EB in vitro. A combination regimen
containing OPC-67683, RFP, and PZA produced a steady
rapid reduction in bacterial load over the ﬁrst 3 mo. These
results suggest that a new regimen containing OPC-67683
could possibly be effective in shortening the clinical treat-
ment duration.
Multiple-drug therapy is a common clinical practice,
particularly in patients with concomitant diseases or con-
ditions. However, whenever two or more drugs are adminis-
tered concurrently, the possibility of drug interactions exists.
Many drug interactions are clinically caused by inhibition of
drug-metabolizing enzymes, such as CYPs, leading to de-
creased metabolic clearance and increased exposure to the
inhibited drug [34–36]. Rifamycin derivatives such as RFP
usually induce CYP3A4 enzymes, remarkably reducing the
Figure 4. Effects of OPC-67683 in an Experimental Mouse Model of TB
(A) ICR mice were inoculated intravenously with M. tuberculosis Kurono. After 28 d, test compounds were administered orally once daily for 28 d (OPC-
67683: 40–0.156 mg/kg, RFP: 20–1.25 mg/kg, INH: 20–1.25 mg/kg, EB: 160–20 mg/kg, SM: 160–20 mg/kg, PZA: 320–40 mg/kg, and PA-824: 40–1.25 mg/
kg; 2-fold dilution). Mean value (n ¼ 5) of log10 CFU was plotted.
(B) BALB/c standard and nude mice were inoculated intravenously with M. tuberculosis Kurono. From the following day, OPC-67683 was administered
orally once daily for 10 d (OPC-67683: 10–0.313 mg/kg, 2-fold dilution). The bar was expressed as mean value and SD (n ¼ 5) of log10 CFU.
(C) The doses of conventional drugs used for evaluating regimen are summarized in this table. The doses set up for using the plasma Cmax achieved in
mice TB model is equivalent to that achieved in humans at the clinical dose.
(D) ICR mice were inoculated intratracheally with M. tuberculosis Kurono. After 28 d, mice were treated for 2 mo with a combination of OPC-67683, RFP,
and PZA (ORZ), or RFP, INH, EB, and PZA (RHEZ) (intensive treatment), and for an additional 2 mo with OPC-67683 and RFP or 4 mo with RFP and INH
(maintenance treatment) (OPC-67683: 2.5 mg/kg, RFP: 5 mg/kg, INH: 10 mg/kg, EB: 100 mg/kg, and PZA: 100 mg/kg). Mean value and SD bar (n¼6) of
log10 CFU was plotted. The fraction refers to the number of mice in which at least one colony was detected of the total number of surviving mice.
doi:10.1371/journal.pmed.0030466.g004
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OPC-67683, a Promising TB Drug Candidatebioavailability of the drug itself as well as other CYP-
intermediated drugs, including protease inhibitors, which
are indispensable in the treatment of HIV/AIDS [37]. It is
therefore important that a new TB drug does not induce nor
is affected by metabolic enzymes. With this in mind, we
studied the interactions between OPC-67683 and metabolic
enzymes. Our results showed that OPC-67683 was hardly
metabolized when exposed to human and animal liver
microsomes and did not have inductive, stimulatory, or
inhibitory effects on CYP enzyme activities at concentrations
up to 100 lM, indicating that OPC-67683, at the expected
therapeutic concentrations, would not be expected to cause
clinically signiﬁcant interactions with other CYP-metabolized
drugs, such as rifamycin derivatives. These results, together
with data supporting non-compromised anti-TB activity in
immunodeﬁcient animals, suggest that OPC-67683 could be
useful in treating TB patients who are also co-infected with
HIV/AIDS.
We conclude that OPC-67683 possesses qualities that could
help address the unmet needs in TB chemotherapy, i.e., the
need for shortened treatment duration, effectiveness against
MDR-TB, ability to be used safely in HIV/AIDS patients, and
the treatment of LTBI. An early Phase II clinical study to
conﬁrm the efﬁcacy in patients is now ongoing.
Furthermore, the Global Alliance for TB Drug Develop-
ment is aiming to establish an entirely new regimen
containing the best combination of new drugs [38]. Develop-
ment and integration of these drugs into the regimen
individually would normally be done in series, taking at least
six years for each drug. We therefore attach importance to
including an evaluation of the effects of OPC-67683 in
combination with not only conventional drugs but also new
drugs as early as possible in order to contribute data
necessary for establishing the best regimen needed to address
the unmet needs in TB treatment.
Supporting Information
Table S1. Viable Count in Lung of Each Group of OPC-67683, RFP,
INH, EB, SM, PZA, and PA-824 after 4 wk of Treatments on the
Experimental Chronic TB Model in Mice
Found at doi:10.1371/journal.pmed.0030466.st001 (43 KB DOC).
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Table 8. Effect of OPC-67683 on CYP1A1/2, CYP2A6, CYP2B6, CYP2C8/9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 Mediated Reactions
in Human Liver
CYP Reaction OPC-67683 or In hibitor Percent of Control
Concentration (lM)
10 30 100
CYP1A1/2 7-Ethoxyresorufin O-deethylation OPC-67683 98.4 102.5 98.6
Furafylline 32.3
7,8-Benzoflavone 3.8
CYP2A6 Coumarin 7-hydroxylation OPC-67683 103.1 97.8 100.8
Diethyldithiocarbamate 38.2
CYP2B6 7-Benzyloxyresorufin O-debenzylation OPC-67683 118.3 112.8 122.3
Orphenadrine 118.8
CYP2C8/9 Tolubutamide methylhydroxylation OPC-67683 107.2 107.8 108.5
Sulfaphenazole 25.5
Quercetin 30.6
CYP2C19 S-mephenytoin 49 -hydroxylation OPC-67683 113.3 106.5 107.6
Tranylcypromine 16.6
CYP2D6 Bufuralol 19 -hydroxylation OPC-67683 99.1 103.3 97.8
Quinidine 0.0
CYP2E1 Chlorzoxazone 6-hydroxylation OPC-67683 110.8 112.4 112.5
Diethyldithiocarbamate 55.0
CYP3A4 Testosterone 6~ b-hydroxylation OPC-67683 117.7 117.7 115.6
Ketoconazole 0.5
CYP3A4 Nifedipine oxidation OPC-67683 101.3 99.9 100.3
Ketoconazole 3.4
The substrate concentrations used for each assay were 0.5 lM 7-ethoxyresorufin, 2 lM coumarin, 1.5 lM 7-benzyloxyresorufin, 400 lM tolbutamide, 100 lM S-mephenytoin, 20 lM
bufuralol, 100 lM chlorzoxazone, 100 lM testosterone, and 50 lM nifedipine. Enzyme incubations and metabolite analysis were carried out in triplicate. Each value represents the mean.
doi:10.1371/journal.pmed.0030466.t008
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many target compounds and supplied derivatives for the screening
toxicity test in animals in large scale. H. Sasaki assumed a main role in
synthesising various compounds, including OPC-67683. Y. Shimoka-
wa was in charge of the drug interaction studies.
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OPC-67683, a Promising TB Drug CandidateEditors’ Summary
Background. One-third of the world’s population is infected with
Mycobacterium tuberculosis, the bacterium that causes tuberculosis (TB).
Most infected people are healthy—the bacteria can remain latent for
years, hidden within cells in the body. However, every year 8 million
people develop active TB, a chronic disease that usually affects the lungs,
and 2 million people die. For most of the second half of the 20th century,
TB was in decline because of the powerful antibiotics that were
developed from the 1940s onwards. The standard treatment for TB—four
antibiotics that have to be taken several times a week for at least six
months to flush out any latent M. tuberculosis bacteria—was introduced
in the late 1970s and saved many lives. Recently, however, efforts to
eradicate TB have been set back by the HIV/AIDS epidemic—people with
damaged immune systems are very susceptible to TB—and the
emergence of multi-drug resistant (MDR) bacteria.
Why Was This Study Done? The treatment for TB is long and
unpleasant, and patients who develop MDR-TB have to be treated with
second-line drugs that are less effective, more expensive, and more toxic.
In addition, for people infected with both HIV and TB, some antiretroviral
and anti-TB drugs cannot be used at the same time. Many drugs are
either activated or removed by enzymes in the liver, so combinations of
these two classes of drugs sometimes alter liver function in a way that
causes clinical problems. There is, therefore, an urgent need for new,
effective anti-TB drugs that attack M. tuberculosis in a different way than
do existing drugs. Such drugs should ideally be active against MDR M.
tuberculosis, work quickly at low doses, be active against latent bacteria,
and have minimal effects on the liver so that they can be used in patients
co-infected with HIV. In this study, the researchers investigated a
chemical called OPC-67683.
What Did the Researchers Do and Find? The researchers identified a
compound that inhibited the production of mycolic acid—an essential
component of the cell wall of M. tuberculosis—and they tested its ability
to kill the organism. They then tested in detail its ability to inhibit
bacterial growth in dishes of antibiotic-sensitive and MDR M. tuberculosis
and isolates from patients. OPC-67683 inhibited the growth of all these
bugs at lower concentrations than the four antibiotics used in the
standard TB treatment. It also killed bacteria hidden within human cells
as well as or better than these drugs. Next, the researchers treated mice
infected with M. tuberculosis with OPC-67683. They found that it reduced
the number of bacteria in the lungs of both normal and immunocom-
promised mice at lower concentrations than the standard drugs.
Furthermore, when combined with two of the standard drugs, it
reduced the time taken to clear bacteria from the lungs by the standard
drug regimen by two months. Finally, the researchers showed that OPC-
67683 had no effects on the liver enzymes that metabolize antire-
trovirals, and, conversely, that the activity of OPC-67683 was not affected
by liver enzymes. Thus, this agent is unlikely to cause clinical problems or
lose its efficacy in HIV patients who are receiving antiretroviral drugs.
What Do These Findings Mean? These results from laboratory and
animal experiments suggest that OPC-67683 could possibly fulfill the
criteria for a new anti-TB drug. OPC-67683 is active against MDR-TB. It is
also active against intracellular TB, which the authors postulate could be
a positive link with the effective treatment of latent TB, and it works
quickly in animals when combined with existing anti-TB drugs.
Importantly, it also disables M. tuberculosis in a unique way and does
not appear to have any major effects on the liver that might stop it from
being used in combination with antiretrovirals. All these preclinical
characteristics now need to be checked in people—many drugs do well
in preclinical studies but fail in patients. These clinical studies need to be
expedited given the upsurge in TB, and, write the researchers, OPC-
67683 needs to be tested in combination with both conventional drugs
and other new drugs so that the best regimen of new drugs for the
treatment of TB can be found as soon as possible.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030466.
  US National Institute of Allergy and Infectious Diseases patient fact
sheet on tuberculosis
  US Centers for Disease Control and Prevention information on
tuberculosis
  MedlinePlus encyclopedia entry on tuberculosis
  NHS Direct Online patient information on tuberculosis from the UK
National Health Service
  World Health Organization information on the global elimination of
tuberculosis
  Global Alliance for TB Drug Development information on why new TB
drugs are needed
PLoS Medicine | www.plosmedicine.org November 2006 | Volume 3 | Issue 11 | e466 2144
OPC-67683, a Promising TB Drug Candidate